{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:40:29Z","timestamp":1768880429685,"version":"3.49.0"},"reference-count":173,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Type 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destruction have been extensively investigated. The strategies based on immunotherapies have recently been incorporated into a panel of existing treatments for T1D, in order to block T-cell responses against beta cell antigens that are very common during the onset and development of T1D. However, a complete preservation of beta cell mass as well as insulin independency is still elusive. As a result, there is no existing T1D targeted immunotherapy able to replace standard insulin administration. Presently, a number of novel therapy strategies are pursuing the goals of beta cell protection and normoglycemia. In the present review we explore the current state of immunotherapy in T1D by highlighting the most important studies in this field, and envision novel strategies that could be used to treat T1D in the future.<\/jats:p>","DOI":"10.3390\/ijms20194789","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T03:03:15Z","timestamp":1569553395000},"page":"4789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-7675","authenticated-orcid":false,"given":"Miriam","family":"Cabello-Olmo","sequence":"first","affiliation":[{"name":"Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-896X","authenticated-orcid":false,"given":"Miriam","family":"Ara\u00f1a","sequence":"additional","affiliation":[{"name":"Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilian","family":"Radichev","sequence":"additional","affiliation":[{"name":"Diabetes Research Group at Sanford Research, Sioux Falls, SD 57104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Smith","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Huarte","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-1432","authenticated-orcid":false,"given":"Miguel","family":"Barajas","sequence":"additional","affiliation":[{"name":"Biochemistry Area, Health Science Department, Faculty of Health Sciences, Public University of Navarra, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.diabres.2013.11.005","article-title":"Diabetes in the young\u2014A global view and worldwide estimates of numbers of children with type 1 diabetes","volume":"103","author":"Patterson","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","article-title":"Epidemiology of type 1 diabetes","volume":"39","author":"Maahs","year":"2010","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.381","article-title":"Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes","volume":"41","author":"Barrett","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0076","article-title":"Genetics of type 1 diabetes: What\u2019s next?","volume":"59","author":"Pociot","year":"2010","journal-title":"Diabetes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S0140-6736(74)91201-X","article-title":"HL-A antigens and diabetes mellitus","volume":"2","author":"Nerup","year":"1974","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fimmu.2017.01898","article-title":"Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response","volume":"8","author":"Clark","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa061267","article-title":"International trial of the Edmonton protocol for islet transplantation","volume":"355","author":"Shapiro","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jacc.2005.05.075","article-title":"Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: A phosphorous-31 magnetic resonance spectroscopy study","volume":"46","author":"Perseghin","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4239\/wjd.v6.i3.380","article-title":"Type 1 diabetes: A predictable disease","volume":"6","author":"Simmons","year":"2015","journal-title":"World J. Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00125-017-4308-1","article-title":"Early prediction of autoimmune (type 1) diabetes","volume":"60","author":"Regnell","year":"2017","journal-title":"Diabetologia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2006.03244.x","article-title":"Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes","volume":"148","author":"Peakman","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2337\/dc15-1429","article-title":"Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: A consensus report","volume":"38","author":"Wherrett","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s00125-012-2523-3","article-title":"Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk","volume":"55","author":"Parikka","year":"2012","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-015-3514-y","article-title":"The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: The TEDDY study","volume":"58","author":"Krischer","year":"2015","journal-title":"Diabetologia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1210\/jc.2017-00569","article-title":"Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives","volume":"102","author":"Bosi","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2019). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142019. Diabetes Care, 42, S13\u2013S28.","DOI":"10.2337\/dc19-S002"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(13)70111-6","article-title":"Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 Month results of a randomised, double-blind, placebo-controlled phase 2 trial","volume":"1","author":"Rigby","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1399-5448.2008.00464.x","article-title":"The TrialNet Natural History Study of the Development of Type 1 Diabetes: Objectives, design, and initial results","volume":"10","author":"Mahon","year":"2009","journal-title":"Pediatr. Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jim.2016.01.011","article-title":"A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease","volume":"430","author":"Zhao","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.4103\/2230-8210.119489","article-title":"Cardiovascular risk in type 1 diabetes mellitus","volume":"17","author":"Slim","year":"2013","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_22","first-page":"1","article-title":"Breeding of a non-obese, diabetic strain of mice","volume":"29","author":"Makino","year":"1980","journal-title":"Jikken Dobutsu"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2337\/diab.26.2.100","article-title":"The spontaneously diabetic Wistar rat: Metabolic and morphologic studies","volume":"26","author":"Nakhooda","year":"1977","journal-title":"Diabetes"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2337\/diab.30.10.887","article-title":"The BB diabetic rat: Profound T-cell lymphocytopenia","volume":"30","author":"Jackson","year":"1981","journal-title":"Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/cimm.1993.1101","article-title":"Transfer of autoimmune diabetes from diabetic NOD mice to NOD athymic nude mice: The roles of T cell subsets in the pathogenesis","volume":"148","author":"Matsumoto","year":"1993","journal-title":"Cell. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/eji.1830220931","article-title":"Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice","volume":"22","author":"Yagi","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"ref_27","first-page":"84","article-title":"Circulating lymphocyte populations and autoantibodies in non-obese diabetic (NOD) mice: A longitudinal study","volume":"70","author":"Pontesilli","year":"1987","journal-title":"Clin. Exp. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2005.08.002","article-title":"A comprehensive review of interventions in the NOD mouse and implications for translation","volume":"23","author":"Shoda","year":"2005","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4161\/hv.27374","article-title":"Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD\/DR4\/B7 mouse","volume":"10","author":"Majji","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature07336","article-title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","volume":"455","author":"Wen","year":"2008","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s00125-012-2564-7","article-title":"Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse","volume":"55","author":"Hansen","year":"2012","journal-title":"Diabetologia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaut.2014.03.005","article-title":"Long term effect of gut microbiota transfer on diabetes development","volume":"53","author":"Peng","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.4049\/jimmunol.1000820","article-title":"Cellular requirements for diabetes induction in DO11.10xRIPmOVA mice","volume":"185","author":"Wesley","year":"2010","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1172\/JCI79271","article-title":"Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis","volume":"125","author":"Nagy","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.TP.0000118410.61419.59","article-title":"Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice","volume":"77","author":"Makhlouf","year":"2004","journal-title":"Transplantation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.gt.3301309","article-title":"Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer","volume":"7","author":"Cameron","year":"2000","journal-title":"Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/10430340360464679","article-title":"Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis","volume":"14","author":"Falkner","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_38","first-page":"a007773","article-title":"Antigen-specific therapeutic approaches in Type 1 diabetes","volume":"2","author":"Tsai","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri2153","article-title":"Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease","volume":"7","author":"Miller","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11892-017-0878-z","article-title":"Combination Immunotherapy for Type 1 Diabetes","volume":"17","author":"Bone","year":"2017","journal-title":"Curr. Diabetes Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI78492","article-title":"Anti-thymocyte globulin\/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes","volume":"125","author":"Haller","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygeno.2013.12.007","article-title":"Temporal profiling of cytokine-induced genes in pancreatic beta-cells by meta-analysis and network inference","volume":"103","author":"Lopes","year":"2014","journal-title":"Genomics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/eji.201546005","article-title":"Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset","volume":"46","author":"Cabrera","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"Franssen","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrendo.2009.271","article-title":"Blockade of interleukin 1 in type 1 diabetes mellitus","volume":"6","author":"Pickersgill","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: Pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: From bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrg3069","article-title":"Understanding type 1 diabetes through genetics: Advances and prospects","volume":"12","author":"Polychronakos","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.1183021","article-title":"Regulation of adaptive immunity by the innate immune system","volume":"327","author":"Iwasaki","year":"2010","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/ajt.12872","article-title":"Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999\u20132010","volume":"14","author":"Balamurugan","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1097\/TP.0b013e31818fe448","article-title":"Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept","volume":"86","author":"Faradji","year":"2008","journal-title":"Transplantation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s00125-009-1390-z","article-title":"Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice","volume":"52","author":"Cembrowski","year":"2009","journal-title":"Diabetologia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3727\/096368910X557263","article-title":"Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice","volume":"20","author":"Rabinovitch","year":"2011","journal-title":"Cell Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2337\/db08-0688","article-title":"Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice","volume":"57","author":"Power","year":"2008","journal-title":"Diabetes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2004-01-0182","article-title":"Antigen-induced regulatory T cells","volume":"104","author":"Vigouroux","year":"2004","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S2213-8587(14)70115-9","article-title":"Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-Month results of a multicentre, randomised, placebo-controlled, phase 2 trial","volume":"2","author":"Griffin","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2337\/db14-0295","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: A multicenter analysis","volume":"63","author":"Franek","year":"2014","journal-title":"Diabetes"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/tcrm.2006.2.4.365","article-title":"Abatacept in the treatment of rheumatoid arthritis","volume":"2","author":"Vital","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-Dose Anti-Thymocyte Globulin (ATG) Preserves beta-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clim.2013.02.003","article-title":"Anti-cytokine therapies in T1D: Concepts and strategies","volume":"149","author":"Nepom","year":"2013","journal-title":"Clin. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1399-5448.2011.00761.x","article-title":"Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes","volume":"12","author":"Sumpter","year":"2011","journal-title":"Pediatr. Diabetes"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1530\/eje.0.1500719","article-title":"A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX)","volume":"150","author":"Crino","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"356ra119","DOI":"10.1126\/scitranslmed.aad9943","article-title":"Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression","volume":"8","author":"Hundhausen","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Tanaka, T., Narazaki, M., and Kishimoto, T. (2018). Interleukin (IL-6) Immunotherapy. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a028456"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2337\/db13-1658","article-title":"Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis","volume":"63","author":"Bogdani","year":"2014","journal-title":"Diabetes"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.2337\/dc13-0327","article-title":"Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes","volume":"37","author":"Aronson","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.it.2011.03.006","article-title":"B cell-directed therapies in type 1 diabetes","volume":"32","author":"Marino","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: An updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cmet.2017.09.016","article-title":"Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy","volume":"26","author":"Coppieters","year":"2017","journal-title":"Cell Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man Phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Alhadj Ali, M., Liu, Y.F., Arif, S., Tatovic, D., Shariff, H., Gibson, V.B., Yusuf, N., Baptista, R., Eichmann, M., and Petrov, N. (2017). Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aaf7779"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/nm1296-1348","article-title":"Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice","volume":"2","author":"Tian","year":"1996","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imm.12867","article-title":"Harnessing the power of regulatory T-cells to control autoimmune diabetes: Overview and perspective","volume":"153","author":"Yu","year":"2018","journal-title":"Immunology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: A unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/db11-1746","article-title":"Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes","volume":"61","author":"Henry","year":"2012","journal-title":"Diabetes"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1600-6143.2008.02234.x","article-title":"Islet transplantation for brittle type 1 diabetes: The UIC protocol","volume":"8","author":"Gangemi","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nri2832","article-title":"New insights into the development of lymphoid tissues","volume":"10","author":"Mebius","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12177","article-title":"Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes","volume":"174","author":"Phillips","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nri2132","article-title":"Tolerogenic dendritic cells and the quest for transplant tolerance","volume":"7","author":"Morelli","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"297","author":"Voltarelli","year":"2007","journal-title":"JAMA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/bmt.2015.294","article-title":"Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: Long-term observations","volume":"51","author":"Snarski","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2017.00167","article-title":"Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes","volume":"8","author":"Malmegrim","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/emm.2013.94","article-title":"Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine","volume":"45","author":"Murphy","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nm.3028","article-title":"The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine","volume":"19","author":"Bianco","year":"2013","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/jcbfm.2013.91","article-title":"Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke","volume":"33","author":"Eckert","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications","volume":"15","author":"Wang","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/JME-17-0117","article-title":"Therapeutic potential of mesenchymal stem cells for diabetes","volume":"59","author":"Moreira","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.2337\/db10-0542","article-title":"Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes","volume":"59","author":"Jurewicz","year":"2010","journal-title":"Diabetes"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2337\/dc15-0171","article-title":"Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 3Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion","volume":"39","author":"Cai","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Pierini, A., Iliopoulou, B.P., Peiris, H., Perez-Cruz, M., Baker, J., Hsu, K., Gu, X., Zheng, P.P., Erkers, T., and Tang, S.W. (2017). T cells expressing chimeric antigen receptor promote immune tolerance. JCI Insight, 2.","DOI":"10.1172\/jci.insight.92865"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of Allograft Rejection by Use of Regulatory T Cells with an MHC-Specific Chimeric Antigen Receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: Immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tenspolde, M., Zimmermann, K., Weber, L.C., Hapke, M., Lieber, M., Dywicki, J., Frenzel, A., Hust, M., Galla, M., and Buitrago-Molina, L.E. (2019). Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J. Autoimmun.","DOI":"10.1016\/j.jaut.2019.05.017"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.1038\/s41598-017-15417-2","article-title":"A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells","volume":"7","author":"Balhuizen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cmmi.1641","article-title":"Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)gammaa as a highly specific biomarker of pancreatic beta cells","volume":"10","author":"Burtea","year":"2015","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cmet.2018.10.007","article-title":"Ectonucleoside Triphosphate Diphosphohydrolase-3 Antibody Targets Adult Human Pancreatic beta Cells for In Vitro and In Vivo Analysis","volume":"29","author":"Saunders","year":"2019","journal-title":"Cell Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/nu4081095","article-title":"Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease","volume":"4","author":"Brown","year":"2012","journal-title":"Nutrients"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1106442","article-title":"Immunity, inflammation, and allergy in the gut","volume":"307","author":"Macdonald","year":"2005","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1126\/science.1104816","article-title":"Host-bacterial mutualism in the human intestine","volume":"307","author":"Backhed","year":"2005","journal-title":"Science"},{"key":"ref_116","first-page":"560","article-title":"Gut bacteria in health and disease","volume":"9","author":"Quigley","year":"2013","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.chom.2013.09.012","article-title":"Microbial modulation of energy availability in the colon regulates intestinal transit","volume":"14","author":"Wichmann","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/pr.2014.170","article-title":"Understanding the role of gut microbiome in metabolic disease risk","volume":"77","author":"Sanz","year":"2015","journal-title":"Pediatr. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/cmi.2017.65","article-title":"Gut microbiota metabolites for sweetening type I diabetes","volume":"15","author":"Aljutaily","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"20858","DOI":"10.1073\/pnas.0808723105","article-title":"Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface","volume":"105","author":"Vaishnava","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2009.08.011","article-title":"Regulatory T cells reinforce intestinal homeostasis","volume":"31","author":"Barnes","year":"2009","journal-title":"Immunity"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1152\/physrev.00045.2009","article-title":"Gut microbiota in health and disease","volume":"90","author":"Sekirov","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4049\/jimmunol.1601519","article-title":"The Influence of the Microbiome on Type 1 Diabetes","volume":"198","author":"Paun","year":"2017","journal-title":"J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2337\/db08-0331","article-title":"The \u201cperfect storm\u201d for type 1 diabetes: The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity","volume":"57","author":"Vaarala","year":"2008","journal-title":"Diabetes"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1210\/jc.2016-3222","article-title":"Duodenal Mucosa of Patients With Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota","volume":"102","author":"Pellegrini","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00125-018-4550-1","article-title":"Aberrant intestinal microbiota in individuals with prediabetes","volume":"61","author":"Allin","year":"2018","journal-title":"Diabetologia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ismej.2010.92","article-title":"Toward defining the autoimmune microbiome for type 1 diabetes","volume":"5","author":"Giongo","year":"2011","journal-title":"ISME J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.diabres.2018.04.032","article-title":"Gut microbiota profiling in Han Chinese with type 1 diabetes","volume":"141","author":"Huang","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Brown, C.T., Davis-Richardson, A.G., Giongo, A., Gano, K.A., Crabb, D.B., Mukherjee, N., Casella, G., Drew, J.C., Ilonen, J., and Knip, M. (2011). Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025792"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1073\/pnas.1219451110","article-title":"Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity","volume":"110","author":"Everard","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.micpath.2016.02.005","article-title":"Akkermansia muciniphila and its role in regulating host functions","volume":"106","author":"Derrien","year":"2017","journal-title":"Microb. Pathog."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","article-title":"An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice","volume":"63","author":"Shin","year":"2014","journal-title":"Gut"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Tanca, A., Palomba, A., Fraumene, C., Manghina, V., Silverman, M., and Uzzau, S. (2018). Clostridial Butyrate Biosynthesis Enzymes Are Significantly Depleted in the Gut Microbiota of Nonobese Diabetic Mice. mSphere, 3.","DOI":"10.1128\/mSphere.00492-18"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2015.01.001","article-title":"The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes","volume":"17","author":"Kostic","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1073\/pnas.1108924108","article-title":"Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice","volume":"108","author":"Kriegel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.copbio.2016.11.010","article-title":"Health benefits of fermented foods: Microbiota and beyond","volume":"44","author":"Marco","year":"2017","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-065X.2011.01080.x","article-title":"Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases","volume":"245","author":"Macia","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2013.08.058","article-title":"Therapeutic potential of fecal microbiota transplantation","volume":"145","author":"Smits","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.nutres.2015.03.002","article-title":"Targeting gut microbiota as a possible therapy for diabetes","volume":"35","author":"He","year":"2015","journal-title":"Nutr. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1475-2891-13-60","article-title":"Gut microbiota, probiotics and diabetes","volume":"13","author":"Gomes","year":"2014","journal-title":"Nutr. J."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Mishra, S.P., Wang, S., Nagpal, R., Miller, B., Singh, R., Taraphder, S., and Yadav, H. (2019). Probiotics and Prebiotics for the Amelioration of Type 1 Diabetes: Present and Future Perspectives. Microorganisms, 7.","DOI":"10.3390\/microorganisms7030067"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JME-16-0054","article-title":"Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice","volume":"58","author":"Zhao","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Wang, L., Wu, Y., Zhuang, L., Chen, X., Min, H., Song, S., Liang, Q., Li, A.D., and Gao, Q. (2019). Puerarin prevents high-fat diet-induced obesity by enriching Akkermansia muciniphila in the gut microbiota of mice. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218490"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.2337\/db13-1777","article-title":"A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes","volume":"63","author":"Ferreira","year":"2014","journal-title":"Diabetes"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diab.44.6.658","article-title":"Interferon expression in the pancreases of patients with type I diabetes","volume":"44","author":"Huang","year":"1995","journal-title":"Diabetes"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/db13-1775","article-title":"Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility","volume":"63","author":"Kallionpaa","year":"2014","journal-title":"Diabetes"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(87)91128-7","article-title":"Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus","volume":"2","author":"Foulis","year":"1987","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","article-title":"Islet cell hyperexpression of HLA class I antigens: A defining feature in type 1 diabetes","volume":"59","author":"Richardson","year":"2016","journal-title":"Diabetologia"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s00125-016-4201-3","article-title":"Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes","volume":"60","author":"Marroqui","year":"2017","journal-title":"Diabetologia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s11033-010-0601-5","article-title":"Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases","volume":"38","author":"Tao","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng.493","article-title":"The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes","volume":"42","author":"Wallace","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2009.04087.x","article-title":"Islet inflammation and CXCL10 in recent-onset type 1 diabetes","volume":"159","author":"Roep","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2337\/db11-0853","article-title":"Expression and regulation of chemokines in murine and human type 1 diabetes","volume":"61","author":"Sarkar","year":"2012","journal-title":"Diabetes"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.173.11.7017","article-title":"CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis","volume":"173","author":"Morimoto","year":"2004","journal-title":"J. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.4049\/jimmunol.167.11.6637","article-title":"IFN-gamma affects homing of diabetogenic T cells","volume":"167","author":"Savinov","year":"2001","journal-title":"J. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management","volume":"124","author":"Ott","year":"2018","journal-title":"Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-017-4536-4","article-title":"IFN-alpha induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells","volume":"61","author":"Marroqui","year":"2018","journal-title":"Diabetologia"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/db16-1250","article-title":"Repurposed JAK1\/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice","volume":"66","author":"Trivedi","year":"2017","journal-title":"Diabetes"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/en.2009-1199","article-title":"Glucose intolerance and impaired insulin secretion in pancreas-specific signal transducer and activator of transcription-3 knockout mice are associated with microvascular alterations in the pancreas","volume":"151","author":"Kostromina","year":"2010","journal-title":"Endocrinology"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Kostromina, E., Wang, X., and Han, W. (2013). Altered islet morphology but normal islet secretory function in vitro in a mouse model with microvascular alterations in the pancreas. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071277"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.bbamcr.2007.05.010","article-title":"The transcription factors Stat5a\/b are not required for islet development but modulate pancreatic beta-cell physiology upon aging","volume":"1773","author":"Lee","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1210\/edrv-15-4-516","article-title":"Insulin-dependent diabetes mellitus as an autoimmune disease","volume":"15","author":"Bach","year":"1994","journal-title":"Endocr. Rev."},{"key":"ref_171","first-page":"306","article-title":"Type 1 diabetes: Molecular, cellular and clinical immunology","volume":"552","author":"Eisenbarth","year":"2004","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2015.08.012","article-title":"T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review","volume":"66","author":"Arif","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fimmu.2018.00392","article-title":"Peptide Immunotherapy for Type 1 Diabetes-Clinical Advances","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:24:42Z","timestamp":1760189082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":173,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["ijms20194789"],"URL":"https:\/\/doi.org\/10.3390\/ijms20194789","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]}}}